全文获取类型
收费全文 | 1366006篇 |
免费 | 99497篇 |
国内免费 | 5697篇 |
专业分类
耳鼻咽喉 | 20036篇 |
儿科学 | 40756篇 |
妇产科学 | 39185篇 |
基础医学 | 190624篇 |
口腔科学 | 40398篇 |
临床医学 | 117184篇 |
内科学 | 265979篇 |
皮肤病学 | 30541篇 |
神经病学 | 108134篇 |
特种医学 | 54907篇 |
外国民族医学 | 452篇 |
外科学 | 211730篇 |
综合类 | 37429篇 |
现状与发展 | 11篇 |
一般理论 | 440篇 |
预防医学 | 93816篇 |
眼科学 | 32432篇 |
药学 | 103837篇 |
32篇 | |
中国医学 | 4777篇 |
肿瘤学 | 78500篇 |
出版年
2018年 | 13232篇 |
2016年 | 11771篇 |
2015年 | 13693篇 |
2014年 | 18936篇 |
2013年 | 27233篇 |
2012年 | 35995篇 |
2011年 | 38068篇 |
2010年 | 22662篇 |
2009年 | 21803篇 |
2008年 | 35729篇 |
2007年 | 38836篇 |
2006年 | 39320篇 |
2005年 | 38110篇 |
2004年 | 36449篇 |
2003年 | 35350篇 |
2002年 | 34641篇 |
2001年 | 64381篇 |
2000年 | 66063篇 |
1999年 | 56057篇 |
1998年 | 14438篇 |
1997年 | 13261篇 |
1996年 | 12592篇 |
1995年 | 12584篇 |
1994年 | 11792篇 |
1992年 | 43002篇 |
1991年 | 41530篇 |
1990年 | 40754篇 |
1989年 | 39712篇 |
1988年 | 37101篇 |
1987年 | 36533篇 |
1986年 | 35002篇 |
1985年 | 33191篇 |
1984年 | 24833篇 |
1983年 | 21033篇 |
1982年 | 12641篇 |
1981年 | 11545篇 |
1979年 | 23899篇 |
1978年 | 17027篇 |
1977年 | 14774篇 |
1976年 | 13340篇 |
1975年 | 15223篇 |
1974年 | 18052篇 |
1973年 | 17544篇 |
1972年 | 16794篇 |
1971年 | 15697篇 |
1970年 | 14875篇 |
1969年 | 14324篇 |
1968年 | 13439篇 |
1967年 | 11992篇 |
1966年 | 11243篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Härter Martin Koch-Gromus Uwe 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2022,65(3):267-269
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - 相似文献
2.
3.
Nanotherapy: New Approach for Impeding Hepatic Cancer Microenvironment via Targeting Multiple Molecular Pathways 下载免费PDF全文
Ahmed A Abd-Rabou Hanaa H Ahmed Safaa H MohamedSoheir E KotobMohamed S Kishta 《Asian Pacific journal of cancer prevention》2022,23(12):4261-4273
Objective: Hepatocellular carcinoma (HCC) microenvironment has been recognized as a key contributor for cancer progression, metastasis, and drug resistance. The crosstalk between tumor cells, the vascular endothelial growth factor (VEGF), and the chemokine (C-C motif) ligand 2 (CCL2) signaling networks mediates immunoinhibitory impact and facilitates tumor angiogenesis. The current investigation aimed at exploring the potent anti-cancer activity of the newly designed nano-based anti-cancer therapy comprising anti-VEGF drug, avastin (AV), and CCR2 antagonist (CR) to counteract HCC and tracking its mode of action in vivo. Methods: The prepared AV, CR, and AVCR nanoprototypes were characterized by nanoscale characterization techniques in our previous work. Here, they are applied for unearthing their anti-cancer properties / mechanisms in hepatic cancer-induced rats via analyzing protein levels and genetic expression of the elements incorporated in the angiogenesis, apoptosis, and metastasis signalling pathways. Results: The present results revealed a significant down-regulation in the angiogenesis, survival and metastasis indices along with up-regulation in the pro-apoptotic mediators upon treatment of hepatic cancer-bearing rats with the novel synthesized nanomaterials when compared with the untreated counterparts. We showed across HCC model that anti-VEGF in combination with CCR2 antagonism therapy leads to sensitization and enhanced tumor response over anti-VEGF or CCR2 antagonism monotherapy, particularly in its nanoscale formulation. Conclusion: The present approach provides new mechanistic insights into the powerful anti-hepatic cancer advantage of the novel nanoprototypes which is correlated with modulating critical signal transduction pathways implicated in tumor microenviroment such as angiogenesis, apoptosis and metastasis. This research work presents a substantial foundation for future studies focused on prohibiting cancer progression and recovery by targeting tumor microenviroment. 相似文献
4.
Xi Tian Yue Wang Wenhao Xu Haidan Tang Shuxuan Zhu Aihetaimujiang Anwaier Wangrui Liu Wenfeng Wang Wenkai Zhu Jiaqi Su Yuanyuan Qu Hailiang Zhang Dingwei Ye 《International journal of cancer. Journal international du cancer》2023,152(1):66-78
In clear cell renal cell carcinoma (ccRCC), glycolysis is enhanced mainly because of the increased expression of key enzymes in glycolysis. Hence, the discovery of new molecular biomarkers for glycolysis may help guide and establish a precise system of diagnosis and treatment for ccRCC. Expression profiles of 1079 tumor samples of ccRCC patients (including 311 patients treated with everolimus or nivolumab) were downloaded from public databases. Proteomic profiles of 232 ccRCC samples were obtained from Fudan University Shanghai Cancer Center (FUSCC). Biological changes, tumor microenvironment and prognostic differences were explored between samples with various glycolysis characteristics. There were significant differences in CD8+ effector T cells, epithelial-to-mesenchymal transition and pan-fibroblast TGFb between the Low and High glyScore groups. The tumor mutation burden of the Low glyScore group was lower than that of the High glyScore group. And higher glyScore was significantly associated with worse overall survival (OS) in 768 ccRCC patients (P < .0001). External validation in FUSCC cohort also indicated that glyScore was of strong ability for predicting OS (P < .05). GlyScore may serve as a biomarker for predicting everolimus response in ccRCC patients due to its significant associations with progression-free survival (PFS). And glyScore may also predict overall survival in patients treated with nivolumab. We calculated the glyScore in ccRCC and the defined glyScore was of strong ability for predicting OS. In addition, glyScore may also serve as a biomarker for predicting PFS in patients treated with everolimus and could predict OS in patients treated with nivolumab. 相似文献
5.
6.
慢性疼痛是一种复杂的身心疾病,包括躯体痛觉异常、认知障碍、负性情绪等多个方面的改变,同时伴随着神经系统的功能以及结构的改变。本文将对慢性疼痛与下行疼痛调节通路、疼痛情感-认知调控网络以及中脑边缘奖赏网络的相关性,以及针刺镇痛的中枢机制相关研究文献进行综述,旨在探讨下行疼痛调节通路、疼痛情感-认知调控网络以及中脑边缘奖赏网络在慢痛发生机制中的作用,为临床治疗慢性疼痛类疾病提供更优势的治疗方案。 相似文献
7.
Clinical and Experimental Medicine - Recently, the use of novel targeted drugs significantly improved the overall response rate (ORR) and survival of patients with relapsed/refractory chronic... 相似文献
8.
Journal of Public Health - The first Covid-19 cases were reported in Malaysia on 25 January 2019 followed by a quiescent period before an upward swing of the cases at the end of February 2020,... 相似文献
9.
10.